TG Therapeutics Crecimiento futuro

Future controles de criterios 6/6

TG Therapeutics se prevé un crecimiento anual de los beneficios y los ingresos de 65% y 33.1% respectivamente. Se prevé que el BPA sea de grow en 65% al año. Se prevé que la rentabilidad de los fondos propios sea de 6.3% en 3 años.

Información clave

49.9%

Tasa de crecimiento de los beneficios

49.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	20.7%
Tasa de crecimiento de los ingresos	30.9%
Rentabilidad financiera futura	54.0%
Cobertura de analistas	Good
Última actualización	25 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

Recent updates

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Aug 03

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jul 19

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Apr 13

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Jan 02

TG Therapeutics: Elucidating The Upcoming Binary

Oct 09

TG Therapeutics: We Are Just Hanging In There

Sep 21

Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

Sep 07

TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials

Aug 25

TG Therapeutics Q2 2022 Earnings Preview

Aug 05

TG Therapeutics And Ublituximab: From Icing To Lifeline

Jul 08

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jun 06

TG Therapeutics: I May Double Down Again

Apr 18

Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe

Feb 08

TG Therapeutics: Double Down On Partial Clinical Hold Non-Issue

Jan 28

TG Therapeutics: Elucidating The Upcoming Binary Event

Dec 27

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:TGTX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	592	217	327	157	5
12/31/2025	413	82	155	83	7
12/31/2024	264	-16	-2	18	8
12/31/2023	234	13	-31	-31	N/A
9/30/2023	190	-26	-42	-42	N/A
6/30/2023	24	-176	-160	-160	N/A
3/31/2023	9	-169	-167	-167	N/A
12/31/2022	3	-198	-176	-176	N/A
9/30/2022	5	-239	-239	-239	N/A
6/30/2022	7	-288	-272	-272	N/A
3/31/2022	8	-326	-283	-283	N/A
12/31/2021	7	-348	-296	-296	N/A
9/30/2021	4	-343	-261	-261	N/A
6/30/2021	2	-345	-251	-250	N/A
3/31/2021	1	-319	-234	-234	N/A
12/31/2020	0	-279	-215	-215	N/A
9/30/2020	0	-231	-193	-193	N/A
6/30/2020	0	-206	-170	-170	N/A
3/31/2020	0	-189	-162	-162	N/A
12/31/2019	0	-173	-133	-133	N/A
9/30/2019	0	-187	-136	-136	N/A
6/30/2019	0	-159	-136	-136	N/A
3/31/2019	0	-167	-134	-134	N/A
12/31/2018	0	-173	-129	-129	N/A
9/30/2018	0	-150	-117	-117	N/A
6/30/2018	0	-148	-107	-107	N/A
3/31/2018	0	-132	-100	-100	N/A
12/31/2017	0	-118	-94	-94	N/A
9/30/2017	0	-111	N/A	-89	N/A
6/30/2017	0	-105	N/A	-81	N/A
3/31/2017	0	-92	N/A	-67	N/A
12/31/2016	0	-78	N/A	-62	N/A
9/30/2016	0	-72	N/A	-57	N/A
6/30/2016	0	-61	N/A	-53	N/A
3/31/2016	0	-62	N/A	-52	N/A
12/31/2015	0	-63	N/A	-45	N/A
9/30/2015	0	-64	N/A	-47	N/A
6/30/2015	0	-68	N/A	-44	N/A
3/31/2015	0	-63	N/A	-36	N/A
12/31/2014	0	-56	N/A	-35	N/A
9/30/2014	0	-43	N/A	-25	N/A
6/30/2014	0	-30	N/A	-18	N/A
3/31/2014	0	-24	N/A	-17	N/A
12/31/2013	0	-20	N/A	-11	N/A
9/30/2013	0	-18	N/A	-7	N/A
6/30/2013	0	-16	N/A	-9	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: TGTX(50.8% al año) es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: TGTXSe prevé que los beneficios de la empresa (50.8% al año) crezcan más deprisa que el mercado US (13.4% al año).

Beneficios de alto crecimiento: TGTXSe espera que los beneficios de la empresa crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: TGTXSe prevé que los ingresos de la empresa (33.1% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: TGTXSe prevé que los ingresos de la empresa (33.1% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: TGTXSe prevé que la Rentabilidad de los fondos propios de la empresa sea muy elevada dentro de 3 años (54%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

TG Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 24%

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 11% to US$32.57

Price target increased by 10% to US$32.43

Price target increased by 9.2% to US$29.07

Forecast breakeven date pushed back to 2024

Recent updates

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Lead Independent Director recently sold US$351k worth of stock

Consensus EPS estimates fall by 24%

TG Therapeutics: Briumvi Growth Story Appears Intact

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$32.57

Price target increased by 10% to US$32.43

TG Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 9.2% to US$29.07

Forecast breakeven date pushed back to 2024

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Price target increased by 11% to US$29.44

CFO, Corporate Secretary & Treasurer recently sold US$809k worth of stock

CFO, Corporate Secretary & Treasurer notifies of intention to sell stock

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

TG Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Price target decreased by 9.1% to US$25.06

Consensus EPS estimates upgraded to US$0.57 loss, revenue downgraded

Forecast breakeven date pushed back to 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Consensus EPS estimates fall by 24%

Chairman recently bought US$1.0m worth of stock

New major risk - Financial position

No longer forecast to breakeven

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Price target decreased by 8.4% to US$29.06

TG Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Consensus revenue estimates increase by 11%

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Independent Director recently sold US$815k worth of stock

Forecast breakeven date moved forward to 2024

Independent Director notifies of intention to sell stock

CFO, Corporate Secretary & Treasurer recently sold US$2.0m worth of stock

CFO, Corporate Secretary & Treasurer notifies of intention to sell stock

Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

Consensus revenue estimates increase by 25%

Price target increased by 43% to US$33.31

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Price target increased by 13% to US$22.56

Consensus EPS estimates fall by 12%

Price target increased by 18% to US$22.63

Full year 2022 earnings: EPS and revenues miss analyst expectations

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Price target increased by 9.1% to US$19.78

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

Price target increased by 9.7% to US$19.25

Lead Independent Director recently sold US$333k worth of stock

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Consensus forecasts updated

Forecast to breakeven in 2025

TG Therapeutics, Inc. Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)

Price target increased to US$17.56

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TG Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Price target decreased to US$14.38

TG Therapeutics: Elucidating The Upcoming Binary

TG Therapeutics: We Are Just Hanging In There

Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics Investors with Losses to Contact Firm’S Attorneys Before Sept. 16Th Deadline in Securities Fraud Class Action

Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

TG Therapeutics, Inc. Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS

TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials

Consensus forecasts updated